

ANDROGEN DEPRIVATION (ADT) + ADVANCED ANDROGEN BLOCKAGE (AAB)

LATITUDE (n 1199)
ADT + abiraterone + prednisone/placebo
OS 0.66 (0.56-0.78)
PFS 0.47(0.39-0.55)
100% high risk patients

STAMPEDE (n 1917)
ADT + abiraterone + prednisone/placebo
OS 0.63 (0.52-0.76)
Volume disease unknown (48% M0)

ENZAMET (n 1125)
ADT+enzalutamide/antiandrogen
OS 0.67 (0.52-0.86)
53% high volume / 47% low
45% concurrent docetaxel
67% synchronous M1

ARCHES (n 1150)
ADT+enzalutamide/placebo
PFS 0.39 (0.30-0.50)
63% high volume / 37% low
18% prior docetaxel
67% synchronous M1

TITAN (n 1052)
ADT+apalutamide/placebo
OS 0.65 (0.53-0.79)
63% high volume / 37% low
11% prior docetaxel
81% synchronous M1

ADT + DOCETAXEL

GETUG-AFU15 (n 385)
ADT +/- docetaxel
OS 0.88 (0.68-1.14)
Median not reached in low-volume patients

CHAARTED (n 790)
ADT +/- docetaxel
OS 0.72 (0.59-0.89)
In high-volume disease: OS 0.63 (0.50-0.79)
In low-volume disease: OS 1.04 (0.70-1.55)

STAMPEDE (n 1086)
ADT +/- docetaxel
OS 0.81 (0.69-0.95)
PFS 0.69 (0.59-0.81)
No differences on high/low metastatic burden

ARASENS (n 1306)
ADT+ docetaxel + darolutamide/placebo
OS 0.68 (0.57-0.80)
100% concurrent docetaxel
Volume disease not evaluated
86% synchronous M1
17% visceral metastases

TRIPLET THERAPY (TT)

PEACE-1 (n 1173)
(ADT +/- docetaxel) +/- abiraterone
OS 0.82 (0.69-0.98)
PFS 0.54(0.46-0.64)
60% concurrent docetaxel
57% high volume / 43% low volume
100% synchronous M1
11% visceral metastases

META-ANALYSIS DOUBLE VS TRIPLET^{1,2,3}

- Mixed treatment comparisons showed **improved OS with NHT+ DOC+ ADT** as compared to **DOC + ADT**, but not when compared to **NHT + ADT** ⁴
- **No OS nor PFS benefit** for patients with mHSPC treated with triple therapy compared to AAB alone
- The beneficial **effect of TT** was especially seen **in the novo high-volume mHSPC cohort**
- **Lack of information** regarding impact of triplet therapy on QoL and in **low volume patients**
- **TT is associated with longer OS and PFS** when compared to docetaxel in mHSPC
- Adverse events are similar for triple therapy than ADT + Docetaxel alone